mAb-话题@MedSci

#mAb#

1302篇内容 | 2896人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912798, encodeId=578a1912e985d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Dermatolog Treat：ixekizumab治疗严重斑块状银屑病患者的疗效和安全性, objectType=article, longId=299288, objectId=c2b8299288cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2b8299288cb, replyNumber=0, likeNumber=86, createdTime=2022-07-30, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2b8299288cb, moduleTitle=J Dermatolog Treat：ixekizumab治疗严重斑块状银屑病患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2b8299288cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912691, encodeId=30601912691da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Gastric Cancer：纳武利尤单抗（nivolumab）治疗不能切除的晚期或复发的胃/胃食管连接处癌（G/GEJ）的疗效和安全性：来自日本的真实研究数据, objectType=article, longId=217859, objectId=d2a621e8599c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2a621e8599c, replyNumber=0, likeNumber=86, createdTime=2022-05-09, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2a621e8599c, moduleTitle=Gastric Cancer：纳武利尤单抗（nivolumab）治疗不能切除的晚期或复发的胃/胃食管连接处癌（G/GEJ）的疗效和安全性：来自日本的真实研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2a621e8599c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912674, encodeId=cf0b19126e439, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV:替曲吉珠单抗（ tildrakizumab ）对中度至重度银屑病患者第28周停药后复发时间的研究, objectType=article, longId=216745, objectId=b9a4216e45c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9a4216e45c3, replyNumber=0, likeNumber=61, createdTime=2021-10-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9a4216e45c3, moduleTitle=JEADV:替曲吉珠单抗（ tildrakizumab ）对中度至重度银屑病患者第28周停药后复发时间的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9a4216e45c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912734, encodeId=e6341912e34dd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效, objectType=article, longId=221635, objectId=7c93221635a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c93221635a0, replyNumber=0, likeNumber=66, createdTime=2022-04-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c93221635a0, moduleTitle=Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c93221635a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912817, encodeId=1cc6191281e41, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV：临床、毛发镜和体内反射共聚焦显微镜对Dupilumab治疗特应性皮炎患者斑秃的评价, objectType=article, longId=300635, objectId=39283006353c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39283006353c, replyNumber=0, likeNumber=101, createdTime=2022-11-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39283006353c, moduleTitle=JEADV：临床、毛发镜和体内反射共聚焦显微镜对Dupilumab治疗特应性皮炎患者斑秃的评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39283006353c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912809, encodeId=2f2d1912809da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV：Risankizumab长期治疗银屑病面积和严重程度指数以及相关的生活质量改善研究, objectType=article, longId=300026, objectId=30e6300026b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30e6300026b8, replyNumber=0, likeNumber=94, createdTime=2022-10-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30e6300026b8, moduleTitle=JEADV：Risankizumab长期治疗银屑病面积和严重程度指数以及相关的生活质量改善研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30e6300026b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912819, encodeId=6d3e19128195c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV:Suckinumab与Ixekizumab治疗脓疱型和红皮病型银屑病的临床比较, objectType=article, longId=301109, objectId=649330110913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649330110913, replyNumber=0, likeNumber=60, createdTime=2022-05-06, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649330110913, moduleTitle=JEADV:Suckinumab与Ixekizumab治疗脓疱型和红皮病型银屑病的临床比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649330110913)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912863, encodeId=4fc41912863fd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ASCO：Denosumab辅助治疗乳腺癌的长期预后, objectType=article, longId=728244, objectId=9c3ce282447f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c3ce282447f, replyNumber=0, likeNumber=80, createdTime=2023-02-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c3ce282447f, moduleTitle=ASCO：Denosumab辅助治疗乳腺癌的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c3ce282447f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912812, encodeId=2a83191281276, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Am Acad Dermatol：Ustekinumab治疗儿童斑块型银屑病的真实经验, objectType=article, longId=300165, objectId=0224300165af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0224300165af, replyNumber=0, likeNumber=55, createdTime=2023-02-15, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0224300165af, moduleTitle=J Am Acad Dermatol：Ustekinumab治疗儿童斑块型银屑病的真实经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0224300165af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912802, encodeId=81501912802b1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV：Dupilumab治疗小儿特应性皮炎患者并发寻常疣后自发消退, objectType=article, longId=299550, objectId=4fad2995506e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fad2995506e, replyNumber=0, likeNumber=57, createdTime=2022-08-14, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fad2995506e, moduleTitle=JEADV：Dupilumab治疗小儿特应性皮炎患者并发寻常疣后自发消退, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fad2995506e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912767, encodeId=05d11912e6727, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=持续mepolizumab治疗能够让重度嗜酸性粒细胞性哮喘患者长期获益, objectType=article, longId=293807, objectId=a75c29380ecf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a75c29380ecf, replyNumber=0, likeNumber=104, createdTime=2022-07-23, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a75c29380ecf, moduleTitle=持续mepolizumab治疗能够让重度嗜酸性粒细胞性哮喘患者长期获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a75c29380ecf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912857, encodeId=ba91191285e45, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌, objectType=article, longId=727377, objectId=ce1ee2737728, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce1ee2737728, replyNumber=0, likeNumber=61, createdTime=2023-04-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce1ee2737728, moduleTitle=Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce1ee2737728)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912681, encodeId=fe6f19126815b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=69, createdTime=2022-08-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912776, encodeId=d7941912e7629, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处, objectType=article, longId=294612, objectId=c7ac294612ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ac294612ce, replyNumber=0, likeNumber=133, createdTime=2022-05-31, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ac294612ce, moduleTitle=Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7ac294612ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912755, encodeId=3b3c1912e55f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=阿尔茨海默病药物 aducanumab 未获准在欧盟使用, objectType=article, longId=292987, objectId=623a29298e1f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623a29298e1f, replyNumber=0, likeNumber=135, createdTime=2022-08-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623a29298e1f, moduleTitle=阿尔茨海默病药物 aducanumab 未获准在欧盟使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623a29298e1f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912872, encodeId=3ef119128e251, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Allergol Int：屋尘螨舌下免疫治疗片作为dupilumab的补充治疗时，对哮喘伴鼻炎的疗效, objectType=article, longId=730536, objectId=49b4e30536c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49b4e30536c5, replyNumber=0, likeNumber=71, createdTime=2022-12-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49b4e30536c5, moduleTitle=Allergol Int：屋尘螨舌下免疫治疗片作为dupilumab的补充治疗时，对哮喘伴鼻炎的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49b4e30536c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912703, encodeId=9e631912e037d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Rheumatology：Guselkumab对活动性银屑病关节炎和骶髂关节炎患者中轴受累的疗效, objectType=article, longId=219178, objectId=43202191e830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43202191e830, replyNumber=0, likeNumber=62, createdTime=2022-03-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43202191e830, moduleTitle=Lancet Rheumatology：Guselkumab对活动性银屑病关节炎和骶髂关节炎患者中轴受累的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43202191e830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912823, encodeId=86c419128234a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, objectType=article, longId=301205, objectId=7d6a3012059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6a3012059f, replyNumber=0, likeNumber=78, createdTime=2022-09-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6a3012059f, moduleTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d6a3012059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912695, encodeId=e8201912695b4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Bimekizumab VS. Secukinumab 治疗斑块状银屑病的疗效及安全性, objectType=article, longId=218429, objectId=869b2184298f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=869b2184298f, replyNumber=0, likeNumber=92, createdTime=2022-08-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=869b2184298f, moduleTitle=NEJM：Bimekizumab VS. Secukinumab 治疗斑块状银屑病的疗效及安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=869b2184298f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912806, encodeId=7009191280654, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Immunother Cancer：Toripalimab（特瑞普利单抗）联合axitinib（阿昔替尼）治疗转移性粘膜黑色素瘤的3年生存更新结果, objectType=article, longId=299734, objectId=92ab299e343d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ab299e343d, replyNumber=0, likeNumber=0, createdTime=2022-11-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ab299e343d, moduleTitle=J Immunother Cancer：Toripalimab（特瑞普利单抗）联合axitinib（阿昔替尼）治疗转移性粘膜黑色素瘤的3年生存更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92ab299e343d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Dermatolog Treat：ixekizumab治疗严重斑块状银屑病患者的疗效和安全性

2022-07-30

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Gastric Cancer：纳武利尤单抗（nivolumab）治疗不能切除的晚期或复发的胃/胃食管连接处癌（G/GEJ）的疗效和安全性：来自日本的真实研究数据

2022-05-09

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV:替曲吉珠单抗（ tildrakizumab ）对中度至重度银屑病患者第28周停药后复发时间的研究

2021-10-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效

2022-04-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV：临床、毛发镜和体内反射共聚焦显微镜对Dupilumab治疗特应性皮炎患者斑秃的评价

2022-11-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV：Risankizumab长期治疗银屑病面积和严重程度指数以及相关的生活质量改善研究

2022-10-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV:Suckinumab与Ixekizumab治疗脓疱型和红皮病型银屑病的临床比较

2022-05-06

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ASCO：Denosumab辅助治疗乳腺癌的长期预后

2023-02-15

仁心济世 (审核中...)

前往app查看评论内容

#mAb#

J Am Acad Dermatol：Ustekinumab治疗儿童斑块型银屑病的真实经验

2023-02-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV：Dupilumab治疗小儿特应性皮炎患者并发寻常疣后自发消退

2022-08-14

snf701207 (审核中...)

前往app查看评论内容

#mAb#

持续mepolizumab治疗能够让重度嗜酸性粒细胞性哮喘患者长期获益

2022-07-23

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌

2023-04-27

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2022-08-27

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处

2022-05-31

snf701207 (审核中...)

前往app查看评论内容

#mAb#

阿尔茨海默病药物 aducanumab 未获准在欧盟使用

2022-08-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Allergol Int：屋尘螨舌下免疫治疗片作为dupilumab的补充治疗时，对哮喘伴鼻炎的疗效

2022-12-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Rheumatology：Guselkumab对活动性银屑病关节炎和骶髂关节炎患者中轴受累的疗效

2022-03-28

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性

2022-09-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Bimekizumab VS. Secukinumab 治疗斑块状银屑病的疗效及安全性

2022-08-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Immunother Cancer：Toripalimab（特瑞普利单抗）联合axitinib（阿昔替尼）治疗转移性粘膜黑色素瘤的3年生存更新结果

2022-11-22

科室
- - 订阅+
  - 更多科室
工具
服务